RT Journal Article
SR Electronic
T1 SARS-CoV-2 evolves increased infection elicited cell death and fusion in an immunosuppressed individual
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.23.22282673
DO 10.1101/2022.11.23.22282673
A1 Gila Lustig
A1 Yashica Ganga
A1 Hylton Rodel
A1 Houriiyah Tegally
A1 Laurelle Jackson
A1 Sandile Cele
A1 Khadija Khan
A1 Zesuliwe Jule
A1 Kajal Reedoy
A1 Farina Karim
A1 Mallory Bernstein
A1 Mahomed-Yunus S. Moosa
A1 Derseree Archary
A1 Tulio de Oliveira
A1 Richard Lessells
A1 Salim S. Abdool Karim
A1 Alex Sigal
YR 2022
UL http://medrxiv.org/content/early/2022/11/24/2022.11.23.22282673.abstract
AB The milder clinical manifestations of Omicron infection relative to pre-Omicron SARS-CoV-2 raises the possibility that extensive evolution results in reduced pathogenicity. To test this hypothesis, we quantified induction of cell fusion and cell death in SARS-CoV-2 evolved from ancestral virus during long-term infection. Both cell fusion and death were reduced in Omicron BA.1 infection relative to ancestral virus. Evolved virus was isolated at different times during a 6-month infection in an immunosuppressed individual with advanced HIV disease. The virus isolated 16 days post-reported symptom onset induced fusogenicity and cell death at levels similar to BA.1. However, fusogenicity was increased in virus isolated at 6 months post-symptoms to levels intermediate between BA.1 and ancestral SARS-CoV-2. Similarly, infected cell death showed a graded increase from earlier to later isolates. These results may indicate that, at least by the cellular measures used here, evolution in long-term infection does not necessarily attenuate the virus.Competing Interest StatementAS received an honorarium for a talk given to Pfizer employees.Funding StatementThis study was supported by the Bill and Melinda Gates award INV-018944 (AS), National Institutes of Health award R01 AI138546 (AS), and South African Medical Research Council Award 6084COAP2020 (AS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Swabs for the isolation of ancestral (D614G.1 and D614G.2), Beta, Delta, D6, D20, D34, D106, and D190 viruses and blood samples to test virus neutralization were obtained after written informed consent from adults with PCR-confirmed SARS-CoV-2 infection who were enrolled in a prospective cohort study at the Africa Health Research Institute approved by the Biomedical Research Ethics Committee at the University of KwaZulu-Natal (reference BREC/00001275/2020). The Omicron/BA.1 was isolated from a residual swab sample with SARS-CoV-2 isolation from the sample approved by the University of the Witwatersrand Human Research Ethics Committee (HREC) (ref. M210752). The sample to isolate Omicron/BA.5 was collected after written informed consent as part of the COVID-19 transmission and natural history in KwaZulu-Natal, South Africa: Epidemiological Investigation to Guide Prevention and Clinical Care in the Centre for the AIDS Programme of Research in South Africa (CAPRISA) study and approved by the Biomedical Research Ethics Committee at the University of KwaZulu-Natal (reference BREC/00001195/2020, BREC/00003106/2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIsolates and raw image files are available upon reasonable request. Sequences of isolated SARS-CoV-2 used in this study have been deposited in GISAID. https://gisaid.org/